MALIGNAT LYMPHOMA -DIAGNOSIS, THERAPY AND PROGNOSIS, HODGKIN’S LYMPHOMAS -HODGKIN’S DISEASE, DIFFUSE LAGRGE CELL B LYMPHOMA - DLCBL
Hodgkin's lymphoma (HL) is a malignant disease of clonal origin from B lymphocytes from the germinal center of the lymph nodes. Many etiologies that are not fully explained, there are risk factors that cause HL disease, the most common of which is the family predisposition, various infections, etc. Hodgkin’s lymphomas are categorized into two main groups according to their specificity and the presence of Reed-Stenberg (RS) cells, neoplastic cells with varying degrees of fibrosis. The diagnosis of LH is confirmed by lymph node biopsy, haemogram, CT of the chest, abdomen, and pelvis, bone marrow biopsy MR, scan, and PET scan.The treatment of HL is done according to protocols using cytostatic to achieve successful therapeutic goals. Diffuse large cell B lymphoma - DGKBL is the most common type of non-Hodgkin lymphoma, occurring in the age group, in the white race in the United States, and equally in both sexes.Characteristically, non-Hodgkin lymphomas are fast-growing tumors with mature B lymphocytes. Diagnostic procedures include blood count, Coombs test, Sedimentation, protein status, electrolyte status, degradation products, LDH, transaminases and liver tests, Flow cytometry. Computerized, PET scan Biopsy and bone marrow aspiration.
Keywords: Hodgkin's lymphoma, lymph nodes, disease, non-Hodgkin cells, lymph nodes, growing tumors, diagnostic procedures, lymphomas
Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339:1506-1514.
2. Canellos GP et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with
ABVD. N Engl J Med 1992; 327:1478-1484.
3. Sureda A et al. Reduced Intensity conditioning compared with conventional allogenic stem cell transplantation
in relapsed and refractory Hodgkin’s Lymphoma: An analysis from Lymphoma Working Party of the European
Group for Blood and Marrow transplantation. J Clin Oncol 2008;26:45-462.
4. Heutte N et al. Quality of life after successful treatment of early stage Hodgkin’s Lymphoma: 10 years follow
up of the EORTCGELA H8 randomised controlled trial. Lancet Oncol 2009; 10:1160-70.
5. Jaffe ES et al. (2001). In Kleihues P, Sobin L eds. WHO Clasifications of Tumours. Lyon; ARC Press.
6. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma.
The Non-Hodgkin’s Lymphoma Clasification Project. Blood, 1997;89:3909-3918.
7. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Prognostic
Factors Project. N Engl J Med, 1993;329:987-994.
8. McLaughlin P et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolend
lymphoma:half of patients respond to a four-dose treatment program. J Clin Oncol, 1998;16:2825-2833.
9. Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in eldery patients with diffuse
large B-cell lymphoma. N Engl J Med, 2002;346:235-242.
10. Philip T et al. Autologous bone marrow transplantation as comperaed with salvage chemotherapy in relapses
of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med, 1995;333:1540-1545.
11. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and
non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 2014;32:3059-3068.
12. WHO. https://www.who.int/en/